318 related articles for article (PubMed ID: 23589109)
1. CD40 immunotherapy for pancreatic cancer.
Vonderheide RH; Bajor DL; Winograd R; Evans RA; Bayne LJ; Beatty GL
Cancer Immunol Immunother; 2013 May; 62(5):949-54. PubMed ID: 23589109
[TBL] [Abstract][Full Text] [Related]
2. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
3. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Beatty GL; Chiorean EG; Fishman MP; Saboury B; Teitelbaum UR; Sun W; Huhn RD; Song W; Li D; Sharp LL; Torigian DA; O'Dwyer PJ; Vonderheide RH
Science; 2011 Mar; 331(6024):1612-6. PubMed ID: 21436454
[TBL] [Abstract][Full Text] [Related]
4. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
6. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Byrne KT; Vonderheide RH
Cell Rep; 2016 Jun; 15(12):2719-32. PubMed ID: 27292635
[TBL] [Abstract][Full Text] [Related]
7. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer.
Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
[TBL] [Abstract][Full Text] [Related]
9. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
11. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.
Liu HC; Davila Gonzalez D; Viswanath DI; Vander Pol RS; Saunders SZ; Di Trani N; Xu Y; Zheng J; Chen SH; Chua CYX; Grattoni A
Adv Sci (Weinh); 2023 Mar; 10(9):e2206873. PubMed ID: 36658712
[TBL] [Abstract][Full Text] [Related]
12. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
13. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
14. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS; Vonderheide RH; O'Hara MH
Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
[TBL] [Abstract][Full Text] [Related]
16. Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
Hundeyin M; Kurz E; Mishra A; Rossi JAK; Liudahl SM; Leis KR; Mehrotra H; Kim M; Torres LE; Ogunsakin A; Link J; Sears RC; Sivagnanam S; Goecks J; Islam KMS; Dolgalev I; Savadkar S; Wang W; Aykut B; Leinwand J; Diskin B; Adam S; Israr M; Gelas M; Lish J; Chin K; Farooq MS; Wadowski B; Wu J; Shah S; Adeegbe DO; Pushalkar S; Vasudevaraja V; Saxena D; Wong KK; Coussens LM; Miller G
Cancer Discov; 2019 Sep; 9(9):1288-1305. PubMed ID: 31266770
[TBL] [Abstract][Full Text] [Related]
17. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
18. The Immune Revolution: A Case for Priming, Not Checkpoint.
Vonderheide RH
Cancer Cell; 2018 Apr; 33(4):563-569. PubMed ID: 29634944
[TBL] [Abstract][Full Text] [Related]
19. CD40 Agonist Antibodies in Cancer Immunotherapy.
Vonderheide RH
Annu Rev Med; 2020 Jan; 71():47-58. PubMed ID: 31412220
[TBL] [Abstract][Full Text] [Related]
20. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.
Burrack AL; Schmiechen ZC; Patterson MT; Miller EA; Spartz EJ; Rollins MR; Raynor JF; Mitchell JS; Kaisho T; Fife BT; Stromnes IM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
